test investor confid margin upsid
disappoint partial off-set op margin came bp better
estim management indic transient issu emerg late expect
improv growth driven part micra av pact av fistula indic
cobalt/crom icd europ expect issu resolv in-lin
management comment see improv growth driven resolut
issu key product launch includ tavr micra av linq robot spine
surgeri see rise interest ahead symplic spyral pivot trial result
march potenti temper mgmt plan updat estim
impact reiter outperform rate target price
org growth fall short expect vs cse transient
issu cite shortfal includ erp upgrad disrupt product ship mitg
slow custom order ahead new product launch cvg variabl
custom buy pattern infus rtg expect org growth
slightli management guidanc exclud potenti impact
management expect provid updat potenti impact viral outbreak
base annual run-rat mdt china busi estim
potenti neg impact growth could much
guidanc trim org sale growth expect
impact previous primarili due shortfal
chang model slightli lower org growth estim rais
ep estim line mgmt revis outlook
valuat target price unchang base ebitda multipl
ntm ebitda estim bil one year forward unchang
risk product delay unexpect execut issu failur progress long-term goal
growth margin potenti new litig regulatori qualiti issu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
mariu zoican univers toronto rotman school manag februari
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
medtron plc global manufactur provid medic devic
equip area cardiac rhythm manag vascular
intervent structur valvular diseas spinal disord
neuromodul surgic equip diabet
one-year valuat scenario base
ev/ebitda ntm ebitda estim bil
one year forward scenario base emerg segment
deliv growth high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ntm ebitda estim bil
one year forward grey scenario base emerg segment
deliv growth high-growth segment grow
growth grow
 close
mariu zoican univers toronto rotman school manag
addit detail takeaway
 heart failur sale bil mil declin organ
arrhythmia manag grew lsd driven pace af micra grew
 drive hsd pacer growth icd ldd driven continu replac cycl
headwind well ramp tyrx suppli along custom wait cobalt crome
crt-d fda approv recal receiv ce mark approv cobalt
crome januari af hsd vs ldd last quarter driven continu uptak
arctic front cryoballoon diagnost grew msd lsd last quarter driven
continu uptak reveal linq heart failur lsd mid-teen crt-p growth
off-set continu crt-d replac management comment lvad stabil
lsd ww compar declin ww
coronari structur heart sale mil mil increas
organ perform led mid-teen ww tavr growth last
quarter management estim mdt tavr busi grew ww market growth
compani continu roll-out evolut coronari growth declin lsd ldd strength
guid cathet off-set declin de cardiac surgeri grew lsd driven continu
strength cardiopulmonari renal denerv off-m pivot data present
march follow investor brief later day
aortic peripher venou sale mil mil increas
organ perform led hsd growth taa driven uptak valiant navion
thorac stent graft system thorac endovascular repair venou grew msd vs lsd last
quarter led on-going adopt venas closur system dcb busi declin
ww compani note sequenti growth
manag expect cvg grow
surgic innov sale bil mil increas organ
advanc surgic msd driven continu convers surgic procedur
open minim invas advanc energi hsd driven contribut new
launch ligasur exact dissector sonicis curv jaw cordless ultrason
dissect system valleylab energi platform advanc stapl lsd driven
endo gia platform tri-stapl technolog colorect procedur gener surgic
flat vs msd last quarter msd growth sutur off-set lower instrument
respiratori gastrointestin renal sale mil mil increas
organ perform led msd growth patient monitor result
nellcor puls oximetri bi brain monitor consum invo cerebr oximetri
sensor consum gi solut grew ldd driven strength across portfolio includ
mid-twenti growth reflux care continuum product line bravo calibration-fre
endoflip imag system well market growth pillcam respiratori grew lsd
in-lin market strength puritan bennett ventil mcgrath
video laryngoscop final renal msd vs flat last quarter due suppli
constraint chronic renal access busi
compani also continu make progress soft tissu robot program
februari announc acquisit privately-held digit surgeri special
surgic artifici intellig ai data analyt digit educ transact
mariu zoican univers toronto rotman school manag
expect immateri compani adjust ep expect meet mdt
long-term financi metric acquisit expect showcas new technolog
upcom sage meet earli april
manag expect mitg grow
brain therapi sale mil mil increas organ
neurovascular mid-teen includ dd growth ischem stroke therapi product
grew back strong adopt solitair stent retriev well
riptid aspir system react aspir cathet hemorrhag hsd growth led
mid-teen growth flow divers neurosurgeri ldd result continu
healthi capit equip sale includ strong demand mazor stealth edit robot
guidanc system mida power surgic instrument
pain therapi sale mil mil decreas organ pain
reflect slowdown market slight share loss intelli sale
grew off-set primari cell devic declin recal nan launch
differenti target multiplex dtm spinal cord stimul modul neuron
glial cell shown statist signific revers pain behavior compar
either low frequenc high frequenc alon anim model expect start dtm
indic expans trial upper limb pre-op spine target drug deliveri
lsd growth driven strong synchrom ii system sale
spine sale mil mil increas organ spine
combin enabl technolog spine-rel enabl technolog revenu reflect
neurosurgeri grew ww last quarter last quarter
lsd spine growth driven mazor implant pull-through well recent product
launch includ infin oct system solid growth prestig lp cervic disc
specialti therapi sale mil mil increas organ
perform driven ldd ent growth driven capit equip sale
stealthstat ent surgic navig system intraop nim nerv monitor system
power ent instrument pelvic health declin lsd compani receiv ce mark
interstim micro neurostimul interstim surescan mri lead januari
compani submit pma fda interstim micro interstim surescan
manag expect rtg grow
ou sale account approxim half total sale vs last quarter
offset competit pressur sale declin ldd compar hsd last quarter
due on-going competit pressur await new product launch cgm growth
driven ww strength integr stand alon cgm system integr cgm
growth led increas cgm penetr well new patient acquisit stand-alon
cgm driven guardian connect smart cgm system grew
last quarter insulin growth driven on-going ou minim
system launch off-set competit pressur compani report hsd growth
western europ dd growth germani itali minim instal base
increas sequenti train activ user respect compani
mariu zoican univers toronto rotman school manag
expect file adult clinic data fda march expect present pivot data
ada confer june
manag expect diabet flat lsd
manag expect sale growth guidanc fx expect repres
headwind compani increas ep guidanc
compani guid ep oper margin expect
expand bp management expect oper margin roughli flat constant
 op margin bp estim
sale net cog off-set lower sg lower expens
non-op lower tax deliv upsid rel estim gross margin
bp y/i bp estim due part increas
china tariff off-set strong oper leverag
estimate bpother bpop bpnon-op bpnet chg y/i mariu zoican univers toronto rotman school manag februari
estimate var salesy/i chg cc chg org chg salesy/i chg cc chg org chg gastro mariu zoican univers toronto rotman school manag februari
chang model
made minor adjust sale estim slightli lower organ
growth estim in-lin new guidanc weve rais ep
estim in-lin guidanc made minor adjust sale
ep estim beyond
figur chang model
 peripher gastrointestin mariu zoican univers toronto rotman school manag februari
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
